Acta Psychiatrica Scandinavica
October 30, 2020
Kristoffer Andreas Aamodt Andersen, Robin Carhart‐Harris, David Nutt et al.
352 citations
A systematic review of 16 papers from 10 clinical trials (7 with psilocybin, 2 with ayahuasca, 1 with LSD) found that serotonergic psychedelics show promise for treating depression, anxiety, obsessive-compulsive disorder, and substance use disorders. Across 188 patients with cancer- or illness-related anxiety and depression, major depressive disorder, OCD, or substance use disorder, the therapy appeared safe, with no severe adverse events reported. Therapeutic effects often lasted weeks to months after only 1 to 3 treatment sessions. The evidence supports feasibility and early efficacy, though larger trials are needed.
Journal of Psychiatric Research
May 26, 2025
Bjørn Holmøy, Tor-Morten Kvam, Kristoffer Andreas Aamodt Andersen et al.
3 citations
A Norwegian translation of the Challenging Experience Questionnaire (CEQ) shows strong reliability and validity for assessing adverse psychedelic experiences. An online survey of 729 Norwegian recreational psychedelic users, mostly male (73%) and aged 26–35 (41%), with 90% having used LSD or psilocybin, confirmed the original 7-factor structure. The translated CEQ demonstrated excellent internal consistency (alpha = 0.94) and good overall model fit. The tool also showed factorial invariance across gender and psychiatric status, and convergent validity through relationships between reported difficulty and factors like fear, grief, insanity, and death. This provides Norwegian researchers with a culturally adapted, psychometrically valid tool for evaluating complex adverse reactions to psychedelic use.
Journal of Psychedelic Studies
July 12, 2024
Kristoffer Andreas Aamodt Andersen, Bjørn Holmøy, Lowan H. Stewart
1 citation
A Norwegian version of the Revised Mystical Experiences Questionnaire (MEQ30) has been developed through rigorous translation and cultural adaptation methods, including two independent forward translations, one back-translation, pilot testing on six psychedelic users, and cognitive debriefing with six experts. The MEQ30 measures mystical-type experiences induced by classic psychedelic drugs like psilocybin, which may underlie therapeutic effects for mental disorders. The Norwegian MEQ30 is ready for use in future trials in Norway, though its psychometric properties have not yet been assessed.